Compare KeyCorp (KEY) vs Sana Biotechnology Inc (SANA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KeyCorp vs Sana Biotechnology Inc — how do they compare? KeyCorp trades at $22.7 (market cap $24.54B), while Sana Biotechnology Inc trades at $3.68 (market cap $1.13B). The key difference: KeyCorp is far larger — about 21.7× Sana Biotechnology Inc's market cap, and KeyCorp pays a 3.58% dividend while Sana Biotechnology Inc pays none. Which is the better fit depends on your goals.
| KEY | SANA | |
|---|---|---|
Market Cap | $24.54B | $1.13B |
Sector | Financials | Health |
52-Week High | $23.99 | $5.92 |
52-Week Low | $16.78 | $2.68 |
Dividend Yield | 3.58% | — |
Enterprise Value | — | $1.05B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KeyCorp (KEY) trades at $22.99, up 1.32% today, with a bullish technical signal supported by moving averages. The stock shows strong fundamental momentum, with Q2 2026 EPS beating estimates at $0.44 versus $0.42 expected, and revenue growth projected to $7.6B in 2026. Recent acquisitions like Clearwater UK aim to expand investment banking fees, while a 3.6% dividend yield adds income appeal. Analyst consensus is bullish with a $29.41 price target, reflecting 28% upside potential.
Outlook is positive due to earnings beats and strategic expansions, but risks include economic uncertainty impacting loan growth and net interest margins. Institutional sentiment is reinforced by CalPERS increasing its stake by 4.7% in Q1 2026, though debt levels and profit margin volatility from 2024's loss warrant caution. The stock remains a value play with a P/E of 13.39, trading below analyst targets.
SANA Biotechnology trades at $3.77, down 0.53% on the day, with strong analyst support showing 82% buy ratings. The stock exhibits bullish technical signals despite negative profitability metrics, including a -152.87% ROE. Recent clinical data presentations at major medical conferences highlight progress in engineered cell therapies for diabetes treatment.
While analyst consensus remains positive with a $9.50 price target, the company faces significant financial challenges with substantial cash burn and negative earnings. Investment opportunity lies in clinical pipeline success, but risks include ongoing losses and shareholder litigation concerns that could impact near-term performance.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About KeyCorp
With assets of over $170 billion, Ohio-based KeyCorp's bank footprint spans 16 states, but it is predominantly concentrated in its two largest markets: Ohio and New York. KeyCorp is primarily focused on serving middle-market commercial clients through a hybrid community/corporate bank model.
Read more on KEY →About Sana Biotechnology Inc
Sana Biotechnology Inc. is a clinical-stage biopharmaceutical company focused on creating and delivering engineered cells as medicines for patients. The company is developing cell therapies for various diseases, including oncology, diabetes, and central nervous system disorders. Sana's core strategy is built around two key technological platforms: in vivo gene delivery to repair cells inside the body and ex vivo cell engineering for therapeutic use.
Read more on SANA →
